The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer
References (0)
Cited by (201)
HER2 targeted therapy in colorectal cancer: New horizons
2022, Cancer Treatment ReviewsHER2 in Colorectal Carcinoma: Are We There yet?
2020, Surgical Pathology ClinicsCitation Excerpt :The overall prognostic significance of ERBB2 amplification in CRC is uncertain. Although early studies reported an association with worse prognosis, these studies considered cytoplasmic expression of ERBB2 as a criterion for positivity.17,44 More recent studies that evaluated only membranous ERBB2 expression have not demonstrated a clear association with prognosis (see Table 1), although a trend toward worse overall survival was identified in one of the largest published studies to date.39
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
2018, Annals of OncologyCitation Excerpt :The prognostic role of HER2 in CRC remains uncertain. A negative prognostic impact of HER2 overexpression was proposed in earlier studies [27, 28], but more recent trials have found no association between HER2 amplification and outcome (Table 1 [16, 19, 21, 22, 25]). However, in one of the largest study cohorts examined (1645 patients with stages I–IV CRC), a trend toward worse OS was reported for the 26 (1.6%) patients with HER2-positive disease compared with those with HER2-negative disease [18].
Proprotein convertase inhibition: Paralyzing the cell's master switches
2017, Biochemical PharmacologyA comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer
2023, British Journal of Cancer